Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) reported promising results from the Phase 3 DAYBREAK study concerning its drug Zeposia (ozanimod) for multiple sclerosis (MS). Over 90% of participants showed an immune response to COVID-19 vaccinations, all serious adverse events were absent. The study demonstrated that 68% of participants were relapse-free with an adjusted annualized relapse rate (ARR) of 0.099 after up to 74 months. These findings emphasize Zeposia's safety and efficacy, reinforcing its value in treatment options for MS.
Bristol Myers Squibb reported third quarter 2022 revenues of $11.2 billion, reflecting an 8% growth in in-line and new product sales, or 13% adjusted for foreign exchange. GAAP EPS rose 9% to $0.75, while non-GAAP EPS increased 3% to $1.99. Significant milestones include FDA approval for Sotyktu, a new psoriasis treatment, and the acquisition of Turning Point Therapeutics. The company updated its 2022 GAAP EPS guidance, primarily due to the acquisition, while reaffirming non-GAAP EPS guidance.
Bristol Myers Squibb (NYSE: BMY) announced positive results from the True North study on Zeposia (ozanimod) for ulcerative colitis (UC), highlighting its effectiveness even after treatment interruption. A significant 86.1% of patients maintained no disease relapse at Week 52, compared to 62.6% in the placebo group. Additionally, Zeposia preserved disease control for up to eight weeks post-treatment interruption. The findings were presented at the ACG 2022 meeting and support the drug's favorable profile for managing moderately to severely active UC.
Bristol Myers Squibb (NYSE: BMY) announced the FDA's acceptance of its supplemental new drug application (sNDA) for CAMZYOS® (mavacamten), aiming to expand its indication to reduce the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM). The sNDA is based on the successful Phase 3 VALOR-HCM study, which met all primary and secondary endpoints with no new safety signals. The FDA has set a Prescription Drug User Fee Act goal date of June 16, 2023.
Bristol Myers Squibb (NYSE: BMY) announced significant results from the Phase 3 CheckMate -76K trial, demonstrating that Opdivo (nivolumab) as an adjuvant therapy improved recurrence-free survival (RFS) for stage IIB and IIC melanoma patients. Opdivo reduced recurrence or death risk by 58% compared to placebo (HR 0.42; p 0.0001) with 12-month RFS rates of 89% versus 79%, respectively. The safety profile was consistent with previous studies, with grade 3/4 treatment-related adverse events at 10% for Opdivo. These results highlight Opdivo's potential as a crucial treatment option for melanoma patients.
Bristol Myers Squibb (NYSE:BMY) announced changes to the dial-in and replay information for its third quarter 2022 earnings conference call set for October 26, 2022, at 8:00 a.m. ET. Investors can participate through a live webcast or by phone, with details provided for dial-in access. A replay will be available starting at 11:30 a.m. ET on the same day until November 9, 2022. The company remains focused on its mission to deliver innovative medicines for serious diseases.
Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.
Bristol Myers Squibb (BMY) has received European Commission approval for Opdualag, a first-in-class combination treatment of nivolumab and relatlimab, for advanced melanoma in patients aged 12 and older with PD-L1 expression 1%. This breakthrough comes from the RELATIVITY-047 trial, which showed Opdualag more than doubled median progression-free survival (PFS) to 6.7 months compared to 3.0 months for nivolumab alone. No new safety concerns were identified. This approval marks a significant advancement in melanoma treatment options within the EU, expanding patient access across member states.
Bristol Myers Squibb (NYSE: BMY) announced that the Phase 3 CheckMate -76K trial for Opdivo (nivolumab) in stage IIB/C melanoma has met its primary endpoint with a significant improvement in recurrence-free survival at a pre-specified interim analysis. The trial showed no new safety signals. Approximately one-third of stage IIB and half of stage IIC melanoma patients may experience recurrence within five years post-surgery. Opdivo's results offer potential advancements in cancer treatment, targeting earlier disease stages to improve patient outcomes.
Bristol Myers Squibb (NYSE: BMY) has announced a quarterly dividend of $0.54 per share, payable on November 1, 2022, to stockholders of record by October 7, 2022. Additionally, a dividend of $0.50 per share on its convertible preferred stock will be paid on December 1, 2022, to stockholders on record by November 8, 2022. This decision reflects the company's commitment to returning value to its shareholders while supporting its mission to develop innovative medicines.